News

b

b

Current News in Drug Discovery

RSS Nature Reviews Drug Discovery
  • Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus June 4, 2026
    Nature Reviews Drug Discovery, Published online: 04 June 2026; doi:10.1038/d41573-026-00094-6The ongoing outbreak of Bundibugyo Ebola virus disease in the Democratic Republic of the Congo highlights the urgent need to bridge therapeutic gaps for non-Zaire ebolaviruses by prioritizing and accelerating development and evaluation of broadly applicable and species-specific filovirus countermeasures.
    Jean B. Nachega
  • Towards mRNA therapeutics 2.0 June 3, 2026
    Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/s41573-026-01459-7mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies, which illustrate how technological advances are […]
    Kenneth R. Chien
  • Informing HIV vaccine design June 3, 2026
    Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00093-7Informing HIV vaccine design
    Sarah Crunkhorn
  • Inhibiting lactate transport reduces lung fibrosis June 3, 2026
    Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00090-wInhibiting lactate transport reduces lung fibrosis
    Sarah Crunkhorn
  • Inhibiting Nipah virus June 3, 2026
    Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00092-8Inhibiting Nipah virus
    Sarah Crunkhorn
  • Understanding Ras inhibitor resistance June 3, 2026
    Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00091-9Understanding Ras inhibitor resistance
    Sarah Crunkhorn
  • Closing the paediatric gap in cancer drug development: a call to industry May 29, 2026
    Nature Reviews Drug Discovery, Published online: 29 May 2026; doi:10.1038/d41573-026-00089-3Despite transformative advances in adult oncology, children with cancer remain systematically underserved by drug development pipelines. We argue that sequential, siloed paediatric development is no longer defensible. Integrating paediatric considerations from drug discovery onwards, and leveraging tumour-agnostic trial designs, regulatory frameworks and adaptive methodologies, offers sponsors […]
    Vivek Subbiah
  • Better data for better medicines: a path to data-driven medicines regulation May 29, 2026
    Nature Reviews Drug Discovery, Published online: 29 May 2026; doi:10.1038/d41573-026-00083-9Over the last decade, progress in science and technology has not only spurred biomedical innovation but has also led to an exponential growth in healthcare and regulatory data. When such data are carefully managed, they can inform medicines developers and regulators to further improve decision making […]
    Francois Domergue

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc.™ participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America™ was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia™.

Attending on behalf of Vitreon America™
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia™ database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia™ database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia™ database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America™ was established with the goal of commercializing their Botanicopeia™ database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com